Recommendations for the Use of In silico Approaches for Next Generation Sequencing Bioinformatic Pipeline Validation

Log in for pricing

(No reviews yet) Write a Review
SKU:
311HZN22-008


Recommendations for the Use of In silico Approaches for Next Generation Sequencing Bioinformatic Pipeline Validation

This contains the webinar recording
Continuing education credit is no longer available for this webinar


Description:

This recorded webinar is based on a forthcoming Joint Report of the Association for Molecular Pathology, Association for Pathology Informatics, and College of American Pathologists, which outlines recommendations and best practices for use of genomic data generated in silico. The major emphasis is on application of such data to validation of assays and especially bioinformatics pipelines. Basic approaches to creating such data and evaluating the relevant limitations are also discussed. Access Practice Guideline here.

Learning Objectives:
  • List the strategies currently employed for creation of genomic data in silico
  • Understand the limitations associated with generating genomic data de novo versus modifying existing data
  • Decide which data is most appropriate for a laboratory's particular needs




Speaker:
Joshua Coleman, MD

University of Utah

Moderator:
Justin Zook, PhD

National Institute of Standards and Technology (NIST)


Duration: 1 Hour
Level of Instruction: Intermediate
Date Recorded: December 8, 2022

Planned and coordinated by the Training and Education Committee

Continuing Education Credit Information

Continuing education credit is no longer available for this webinar 


Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.